Study guide

4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation

CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide

2 Chapter 2: Cancer & Cancer Treatment Modalities

2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)

3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging

3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors

4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy

4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome

5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination

5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes

6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety

6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology

7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics

7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics

4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation

Key Takeaways Explain This Topic AI

Irinotecan induces dual lower GI toxicities: acute cholinergic diarrhea (<24 hours post-infusion, managed with IV/SQ atropine) and delayed secretomotor diarrhea (>24 hours, driven by SN-38 mucosal damage, managed with high-dose loperamide).

Common Terminology Criteria for Adverse Events (CTCAE v5.0) Grade 3 diarrhea is defined by an increase of >=7 stools per day over baseline, incontinence, or limitation in self-care ADLs requiring hospitalization or IV fluids.

Radiation enteritis occurs in acute form (during therapy, crypt cell mitotic arrest, managed with low-fat, low-lactose, low-insoluble fiber diet) and chronic form (>6 months post-RT, obliterative endarteritis, submucosal fibrosis, strictures, requiring peptide EN or TPN).

Post-gastrectomy Dumping Syndrome is classified into Early Dumping (10-30 min, hyperosmolar fluid shifts, dizziness, cramps) and Late Dumping (1-3 hours, rapid glucose absorption causing reactive hypoglycemia); managed by small dry meals, simple sugar restriction, liquid separation by 30-60 min, and soluble pectin fiber.

Last updated: August 2026

4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation

Lower gastrointestinal toxicities resulting from antineoplastic chemotherapy agents, pelvic or abdominal radiation therapy, and surgical resections present severe challenges in oncology care. Uncontrolled diarrhea, mucosal malabsorption, radiation enteropathy, and severe constipation put patients at immediate risk for severe dehydration, hemodynamic instability, electrolyte exhaustion (hypokalemia, metabolic acidosis), acute kidney injury, and rapid malnutrition.

Chemotherapy-Induced Diarrhea (CID)

CID is most commonly caused by fluoropyrimidines ( 5-Fluorouracil [5-FU] , Capecitabine ) and Irinotecan (CPT-11), as well as targeted tyrosine kinase inhibitors (TKIs like lapatinib, afatinib, and neratinib).

Irinotecan Dual-Mechanism Toxicity Protocol

Irinotecan produces two pathophysiologically distinct types of diarrhea that require completely different pharmacological interventions:

Acute Cholinergic Diarrhea (<24 hours post-infusion): Caused by direct inhibition of acetylcholinesterase by the irinotecan parent compound, leading to systemic cholinergic excess. Manifests with abdominal cramping, diaphoresis, hyper-salivation, lacrimation, miosis, and watery diarrhea. Treatment: Intravenous or Subcutaneous Atropine (0.25 to 1.0 mg) .

Delayed Secretomotor Diarrhea (>24 hours post-infusion, peaking at Days 3–5): Caused by the active lipophilic metabolite SN-38 . Glucuronidated in the liver to inactive SN-38G, it is excreted into bile where intestinal β \beta β -glucuronidase enzymes reconvert it back to toxic free SN-38. Free SN-38 causes mucosal denudation, enterocyte apoptosis, mucosal inflammation, and massive hypersecretion of water and electrolytes. Treatment: Aggressive High-Dose Loperamide Protocol .

CTCAE v5.0 Diarrhea Grading System

CTCAE Grade Clinical Criteria & Stool Frequency

Grade 1 Increase of <4 stools/day over baseline; mild increase in ostomy output relative to baseline.

Grade 2 Increase of 4 to 6 stools/day over baseline; moderate increase in ostomy output; limiting instrumental ADLs.

Grade 3 Increase of ≥ 7 \ge 7 ≥ 7 stools/day over baseline; incontinence; limiting self-care ADLs; hospitalization or IV fluids required.

Grade 4 Life-threatening consequences; urgent intervention indicated (hypovolemic shock, severe electrolyte collapse, sepsis).

Grade 5 Death.

High-Dose Loperamide & Second-Line Protocols

Loperamide Protocol: At the very first unformed stool, the patient takes 4 mg of oral loperamide , followed by 2 mg every 2 hours (or 4 mg every 4 hours during sleep) until the patient is completely free of diarrhea for 12 consecutive hours . Package label maximums (16 mg/day) are safely exceeded under medical oversight during CID.

Second-Line Pharmacotherapy: If diarrhea persists beyond 24–48 hours despite high-dose loperamide, initiate Octreotide (100 to 500 mcg SubQ or IV TID) . Octreotide is a somatostatin analog that inhibits gastrointestinal hormone secretion, reduces intestinal motility, and drastically decreases fluid and electrolyte secretion.

Radiation Enteritis & Colitis

Ionizing radiation to abdominal or pelvic fields (cervical, prostate, rectal, pancreatic cancers) damages rapidly proliferating intestinal crypt stem cells.

Feature Acute Radiation Enteritis Chronic / Late Radiation Enteritis

Onset During therapy or within 1 to 6 weeks of radiation completion >6 months to years (or decades) post-radiation

Pathophysiology Crypt cell mitotic arrest, villous atrophy, acute mucosal inflammation, hypermotility Progressive obliterative endarteritis , submucosal ischemia, collagen deposition, fibrosis, strictures, fistulae, short bowel syndrome

Malabsorptive Profile Transient lactose intolerance, bile acid malabsorption, hypermotility Permanent fat, protein, B 12 B_{12} B 12 ​ , and fat-soluble vitamin malabsorption; bacterial overgrowth (SIBO); intestinal obstruction

MNT Recommendations Low-fat (<20% kcal) , low-lactose , low-insoluble fiber , high soluble fiber (pectin, psyllium), Oral Rehydration Solutions (ORS) Tailored enteral nutrition (elemental/peptide-based), low-fat diet, MCT oil, Parenteral Nutrition (PN) for strictures/obstruction

Post-Gastrectomy & Post-Surgical Dumping Syndrome

Surgical procedures such as total or subtotal gastrectomy, Roux-en-Y reconstruction, or Whipple procedures destroy or bypass pyloric sphincter regulation, resulting in rapid delivery of hyperosmolar chyme into the proximal jejunum. Surgical Resection / Pyloric Loss

  • │
  • ▼
  • Rapid Bolus of Hyperosmolar Chyme into Jejunum
  • │
  • ├─────────────────────────────────────────┐
  • ▼ ▼
  • Early Dumping (10-30 min) Late Dumping (1-3 hours)
  • Massive Intravascular Fluid Shift • Rapid Intestinal Glucose Absorption
  • Intestinal Lumen Distension • Exaggerated Insulin Surge
  • Cramps, Diarrhea, Tachycardia • Reactive Hypoglycemia
  • Orthostatic Hypotension • Diaphoresis, Tremors, Confusion
  • MNT Protocol for Dumping Syndrome

Consume 6 to 8 small, dry meals daily.

Strictly restrict simple sugars and refined carbohydrates (table sugar, candy, fruit juices, sodas) to prevent hyperosmolar shifts and hyperinsulinemia.

Separate liquid intake from solid foods by 30 to 60 minutes (consume completely dry meals to prevent flushing chyme into the bowel).

Supplement meals with soluble viscous fiber (pectin, guar gum, psyllium) to increase chyme viscosity, delay gastric emptying, and slow glucose absorption.

Recline or lie recumbent for 20 to 30 minutes post-meal to reduce gravity-driven intestinal transit.

Constipation & Paralytic Ileus in Supportive Oncology

Constipation in cancer patients stems from opioid analgesics, 5-HT3 antiemetics, vinca alkaloids ( Vincristine , Vinblastine ), dehydration, hypercalcemia, and immobility.

Vinca Alkaloid Neurotoxicity: Vincristine causes direct damage to the autonomic myenteric plexus, leading to paralytic ileus, severe colonic impaction, and pseudo-obstruction.

Pharmacological Management: Combine a bowel stimulant ( Senna , Bisacodyl ) with an osmotic laxative ( Polyethylene Glycol [Miralax] , Lactulose ). For Refractory Opioid-Induced Constipation (OIC), utilize Peripherally Acting Mu-Opioid Receptor Antagonists ( PAMORAs like Methylnaltrexone or Naloxegol ), which reverse constipation without neutralizing central analgesia.

Clinical Calculation & Worked Case Example

Patient Profile: A 64-year-old male receiving FOLFIRI (Irinotecan + 5-FU) presents on Day 4 post-chemotherapy with 9 watery stools in 24 hours, weakness, orthostatic dizziness, and serum potassium of 3.1 mEq/L 3.1\text{ mEq/L} 3.1 mEq/L .

Care Plan Analysis:

CTCAE Grading: 9 stools/day over baseline equals CTCAE Grade 3 Diarrhea .

Pathophysiology: Delayed secretomotor diarrhea caused by SN-38 metabolite.

Intervention: Immediately initiate high-dose loperamide (4 mg initial, 2 mg q2h). Admit for IV isotonic saline hydration with 20 mEq KCL/L 20\text{ mEq KCL/L} 20 mEq KCL/L . If diarrhea continues >24 hours, add Octreotide 150 mcg SubQ TID 150\text{ mcg SubQ TID} 150 mcg SubQ TID . Provide isotonic ORS and low-fat, low-insoluble fiber diet.

Loading diagram... Irinotecan Dual-Mechanism Diarrhea Pathophysiology & Management